Abatatx offers a managed WordPress hosting service that automates domain verification, DNS configuration, and account provisioning to prevent common setup errors. The platform provides guided onboarding, real‑time support, and monitoring alerts, enabling small to medium businesses and individual site owners to launch and maintain WordPress sites with minimal downtime and technical effort.

Able utilizes artificial intelligence to streamline the commercial loan processing workflow, significantly reducing the time required for loan approvals. By automating data analysis and document verification, the platform enhances operational efficiency and minimizes the risk of human error in financial assessments.

Abyss Analytics transforms complex healthcare data into actionable intelligence for providers, payors, and investors. The platform uses AI and machine learning to surface insights, identify process inefficiencies, and drive cost reduction. This analysis supports strategic decision-making, including accurate M&A valuation and performance benchmarking within the healthcare sector.

Agios develops oral, disease‑modifying therapies that target metabolic enzymes to treat rare hemolytic anemias and phenylketonuria. By leveraging its expertise in cellular metabolism, the company creates PK activators and PAH stabilizers that improve red blood cell durability and normalize phenylalanine levels, offering long‑term benefits for patients and their clinicians.

The startup has developed a healthcare application that integrates evidence-based therapy with neuroscience to facilitate the identification, measurement, and treatment of social anxiety. This application enables users to effectively manage their stress levels and reduce anxiety through targeted therapeutic techniques.

Anara is an AI-powered research workspace that helps academics and students accelerate literature review and knowledge synthesis. It allows users to query academic databases, extract verifiable insights from documents, and automatically generate study aids like flashcards and quizzes.

ARTBIO is developing a new class of alpha radioligand therapies that utilize Pb-212 isotopes to target and destroy cancer cells while minimizing damage to healthy tissues. This approach addresses the limitations of existing beta radioligand therapies by offering potentially improved efficacy and safety for patients with solid tumors.

Asher Bio develops cis-targeted immunotherapies designed to selectively activate specific immune cell types for therapeutic benefit. This platform engages two molecules on the same cell to achieve high selectivity, optimizing efficacy while minimizing off-target toxicity. The lead candidate is a cis-targeted IL-2 therapy specifically activating CD8+ effector T cells.

RecyclX provides an end-to-end chain of custody platform that utilizes a 4-factor data validation algorithm, dynamic QR codes, and blockchain integration to ensure traceability and transparency in the recycling process. The platform generates Digital Product Passports, enabling consumers to access verified information about the lifecycle of recycled products, promoting informed choices and sustainable practices.

Azalea Therapeutics develops precision genomic medicines by engineering T cells directly inside the body for cancer immunotherapy. The company utilizes Envelope Delivery Vehicles (EDVs) to selectively deliver genome editing cargo to T cells. This approach aims to create faster, more accessible, and potent cell therapies by avoiding complex ex vivo manufacturing.

This software platform assists brands in assessing, enhancing, and communicating the environmental performance of their products, ingredients, and packaging. It provides tools to track evolving retailer standards and regulatory requirements quickly, integrating sustainability data directly into product development cycles. The service enables transparent sustainability communication to demonstrate brand commitment effectively without greenwashing.

Blueprint offers personalized brain health coaching and lifestyle optimization plans that focus on sleep, nutrition, exercise, and stress management to prevent dementia. By providing expert guidance and tailored strategies, the company empowers clients to enhance their cognitive health and maintain mental vitality as they age.

Candid Therapeutics develops targeted therapies for autoimmune diseases, focusing on novel mechanisms of action. Their pipeline includes candidates designed to modulate immune pathways and improve patient outcomes. The company aims to address unmet clinical needs with scientifically validated drug candidates.

CARGO Therapeutics is developing tri-specific CAR T-cell therapies designed to target and eliminate B-cell lymphoma cells effectively. This approach aims to provide patients with potentially curative treatment options that traditional therapies may not achieve.

Casma Therapeutics utilizes its PHLYT™ platform to enhance autophagic degradation of damaged cellular components, targeting diseases that existing therapies cannot effectively address. By reprogramming the natural cellular process of autophagy, the company aims to improve patient outcomes in conditions resistant to current drug treatments.

The startup provides a cross-border payment solution tailored for small and medium-sized enterprises (SMEs) and e-commerce businesses, utilizing blockchain technology to enhance transaction security and transparency. This service addresses the challenges of high fees and slow processing times associated with international payments, enabling faster and more cost-effective financial transactions.

Clasp Therapeutics develops precision immunotherapies using proprietary pHLAre™ T cell engagers that target mutated protein fragments on cancer cells, enabling the immune system to selectively destroy tumors with specific driver mutations. This approach addresses the limitations of current immuno-oncology treatments by expanding therapeutic options for patients with hard-to-treat cancers.

Dill provides construction suppliers with a platform to automate credit applications and streamline accounts receivable processes. The system enables white-labeled online payment portals for customers to pay via ACH or credit card, accelerating cash flow. By automating statements, reminders, and reconciliation, Dill reduces manual AR work and speeds up customer onboarding.

Faze Medicines is a biotechnology company focused on developing targeted therapies using advanced gene editing techniques to address genetic disorders. Their approach aims to enhance treatment precision and improve patient outcomes by directly modifying disease-causing genes.

IB is an insurance management app that digitizes and consolidates users' insurance policies, allowing for easy access and sharing among family members. The platform identifies potential claims based on user-reported incidents, helping to prevent missed opportunities for insurance payouts.

Marea Therapeutics utilizes large-scale human genetic data and adipocyte biology to develop therapies targeting remnant cholesterol, a key driver of cardiometabolic diseases. Their lead program, MAR001, is a monoclonal antibody designed to lower remnant cholesterol levels, addressing a critical unmet need for patients at high risk of cardiovascular events despite existing treatments.

Merida Biosciences develops novel precision therapies targeting the pathogenic drivers of antibody-driven autoimmune diseases. Their platform aims to eliminate disease roots with high specificity, offering durable clinical responses where current non-specific treatments fall short. The company focuses on the discovery and development of highly specific immunotherapies for patients suffering from autoimmune and allergic disorders.

Rapport Therapeutics uses its RAP technology platform to identify receptor‑associated proteins (RAPs) and develop small‑molecule drugs that selectively bind these targets, delivering neuroanatomical and subunit specificity for CNS disorders. By focusing on precise modulation of receptors in defined brain regions, its programs—such as the TARPγ8‑selective AMPA‑receptor modulator RAP‑219 for focal epilepsy—aim to provide safer, more effective treatments for conditions like epilepsy, chronic pain, and hearing disorders.

Re is an on‑chain reinsurance protocol that tokenizes real reinsurance treaties, issuing fully collateralized tokens backed by verified insurance premiums. The platform provides institutional investors and insurers with regulated, transparent access to the $800B+ reinsurance market, delivering 8‑16% annual yields that are largely uncorrelated with traditional assets while maintaining defined risk limits and underwriting discipline.